AI and brain-computer interface allow speechless ALS patient to work a full-time job is attracting attention across the tech world. Analysts, enthusiasts, and industry observers are watching closely to see how this story develops.
This update adds another signal to a fast-moving sector where product decisions, platform changes, and competition can quickly shape the market.
The hardware isn't new, but a UC Davis research team's machine learning-powered method of translating brain activity in an ALS patient into sentences with 92% accuracy is
Imagine being paralyzed so badly that not only can't you move your hands or feet, but you can't speak either. For years, brain computer interfaces have presented the tantalizing promise of reading brainwaves well enough to allow a person to communicate and access a PC.
Now, a new breakthrough shows how someone can talk and even work a job while afflicted with a motion-robbing disease.
A team of scientists from the University of California, Davis, published a paper Monday detailing a years-long study of a brain computer interface (BCI) platform implanted in a patient with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), which destroys motor neurons and causes loss of motor control and eventual paralysis. as reported by the team, their patient, Casey Harrell, has been living with BCI implants since 2023 that are still working today, giving him the ability not only to control a computer cursor with his thoughts, but also to speak.
The Davis team is part of a broader coalition of universities with the US Department of Veterans Affairs known as BrainGate. They're working on a variety of neuroscience projects to do things like restore speech, use computers, and, in some cases, restore movement. In Harrell’s case, the Davis team was trying to figure out how to turn experimental tech into something long lasting and practical for use outside of a laboratory.
Davis neurosurgeon David Brandman, co-principal investigator and co-senior author of the paper published Monday, as well as the surgeon who placed Harrell’s implant, described the results his team published as the crossing of a threshold in BCI tech innovation: Not only has Harrell’s implant been working well with daily use since 2023, but it’s also incredibly accurate.
In controlled tests, the platform managed to synthesize sentences from Harrell’s brain activity with 99 percent accuracy; outside of the lab in daily use, Harrell still assessed it as being accurate 92 percent of the time.
“The key thing to me is that it’s enabling everyday communication for a guy who wants to talk but can’t,” Brandman told The Register in an interview. “Despite being paralyzed [Harrell] has gone back to work full time and has meaningful conversations with his daughter who’s never heard the sound of his voice.”
Prior work in the BCI space, Brandman told us, has either required researchers to be in a patient’s home whenever they’re using the tech, or for the patient to come to the researchers. That’s not the case here, with the platform allowing Harrell’s home care team to hook him up to the platform themselves, enabling him to use the device for more than 3,800 hours in the past few years. Based on the time the study was filed (It published Monday but went into peer review in July 2025) that would mean Harrell was using the device for more than five hours a day, on average.
“It is a life that is more full of dynamic action and with friends and family, with colleagues, and it is something that allows me to communicate more in my natural way of communicating than any other tech innovation that I have experienced,” Harrell told UC Davis via his BCI platform.
Brandman is no stranger to BCI tech innovation: Along with being a key figure in the BrainGate consortium, he’s also worked as study principal in investigating the safety of commercial BCI tech from Paradromics, one of the leading companies in the space alongside Synchron and Neuralink.
As Brandman explained it, the Davis study didn’t involve any purpose-built hardware, instead making use of an existing BCI design produced by Blackrock Neurotech. The big advancement, says the Davis neurosurgeon, is with his team’s use of machine learning tech innovation.
The lab has built its own software platform for operating BCI devices known as Brain-computer interface for Rapidly Adaptive Neural Decoding (BRAND, which Brandman told us was coincidentally named), which UCD postdoctoral fellow Nick Card built machine learning algorithms for. BRAND is now used across the BrainGate consortium, and is where the secret sauce of the project’s success lies.
as reported by the paper, BRAND’s AI algorithms are able to translate activity in Harrell’s ventral precentral gyrus, the part of the brain that controls motor function in the face, mouth, and jaw, into English-language phonemes. Additional algorithms in the software map those phonemes to words, and words to sentences. The end result is some very precise speech synthesis that allows Harrell to work full time as an environmental advocate.
As for when the tech innovation being developed by the UCD team might hit the commercial market, Brandman tells us that other technologies in the BCI space, such as those from Neuralink and others, are all working on tech with the same sorts of goals. His team’s objective is just to prove that BCI platforms are more than just dead-end laboratory experiments.
He likened the current state of BCI tech innovation to early pacemakers, which started off in the 1950s having to be wired to hardware outside the body that was often connected to large batteries or directly tethered to the wall. Fast forward seventy years, and pacemakers are so simple to implant they’re often done in an outpatient procedure.
“We’re at the early stages of this kind of tech innovation,” Brandman said. “Casey has demonstrated that this kind of tech is practical.”
Harrell may be wired up to a bunch of bulky external computers now, but combine the Davis UCD team’s AI advancements with the hardware work being done by other firms, and the future looks brighter for a lot of people whose lives are limited by paralysis and other impairments.
“I want desperately to not be unique or special, because that will mean I no longer have the disease or that everyone that has the disease like me can get [BCI] prescribed to them,” Harrell said.
BrainGate is currently accepting applications for future study participants. ®
Why This Matters
This development may influence user expectations, future product strategy, and the competitive balance inside the broader technology industry.
Companies in adjacent segments often react quickly to similar moves, which is why stories like this tend to matter beyond a single announcement.
Looking Ahead
The full impact will become clearer over time, but the story already highlights how quickly the modern tech landscape can evolve.
Observers will continue tracking the next steps and how they affect products, users, and the wider market.
